PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Profitability reveals how effectively the business turns revenues into profits. Higher and improving margins or returns on capital suggest a durable competitive advantage, supporting a stronger intrinsic valuation.
5.18%
ROE exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.36%. Joel Greenblatt would check if high returns reflect a sustainable advantage.
4.54%
ROA of 4.54% while Drug Manufacturers - Specialty & Generic median is zero. Peter Lynch would see if minimal profitability can widen over time.
0.43%
ROCE of 0.43% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss would see if moderate profitability can widen vs. peers.
63.23%
Gross margin near Drug Manufacturers - Specialty & Generic median of 57.76%. Charlie Munger might attribute it to standard industry practices.
22.61%
Margin of 22.61% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss would see if moderate profitability can be leveraged further.
245.74%
Net margin of 245.74% while Drug Manufacturers - Specialty & Generic is zero. Walter Schloss would examine if modest profitability can expand.